Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 8.038
- Book/Share 2.4743
- PB 21.3275
- Debt/Equity 0.1154
- CurrentRatio 1.5942
- ROIC 0.2452
- MktCap 11369507580.0
- FreeCF/Share 1.0821
- PFCF 47.3302
- PE 71.2575
- Debt/Assets 0.0711
- DivYield 0
- ROE 0.3597
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Jumping Into The FDA Gamble: Initiating Hims & Hers With A Buy
Published: March 20, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health, Inc. stock surged to $68, and the subsequent 50% crash is the talk of the town. I'm eyeing it as a favorable high-risk, high-reward play. HIMS stock plummeted after the FDA halted approval of its top-selling GLP-1 weight loss drug, which is priced at $165 and offers the same as Ozempic, priced on average $1,000. The FDA's pending decision on semaglutide's shortage status, due April 22nd, is crucial; a favorable ruling could boost HIMS stock significantly.
Read More
Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There
Published: March 20, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers (HIMS) is a newfangled tele-health company that started to ride the waves of GLP-1 weight loss medications. As waves go, this one's given the stock a heck of ride; way up and then all the way back down. More big moves could happen in the near term. Looking deeper and reading a lot of tea leaves, I envision HIMS growing from a peddler of feel-good non-essential medications into a serious player in the emerging personalized medicine field.
Read More
Why Hims & Hers Stock Tumbled on Tuesday
Published: March 18, 2025 by: The Motley Fool
Sentiment: Negative
Hims & Hers Health (HIMS -6.95%) stock slid 7.4% through 11:10 a.m. ET Tuesday after Bank of America raised its price target on the pharmaceuticals stock in the worst way possible.
Read More
Why Hims & Hers Health Stock Just Popped
Published: March 11, 2025 by: The Motley Fool
Sentiment: Neutral
Roller-coaster healthcare stock Hims & Hers Health (HIMS 5.26%), whose stock got devastated last week by worries that it would be shut out of the GLP-1 market, got a reprieve from the Food and Drug Administration (FDA) on Monday.
Read More
Hims & Hers: The Odds Are In Your Favor, Here's How To Take Advantage (Rating Upgrade)
Published: March 07, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health is now reasonably valued after its large drop, making it a cautious Buy due to its high growth potential. The company's revenue grew 69% YoY to $1.5 billion, driven by a 45% increase in subscribers and higher average revenue per subscriber. To mitigate risk, consider selling call options against HIMS shares, leveraging high implied volatility for a favorable risk-reward proposition.
Read More
Novo Nordisk's Cheaper Wegovy Offering Is Bad News for Hims & Hers
Published: March 05, 2025 by: Barrons
Sentiment: Negative
The announcement comes weeks after the FDA declared that Wegovy is no longer in shortage.
Read More
Hims & Hers' Fall From Grace Is Warranted - Still No Margin Of Safety
Published: March 03, 2025 by: Seeking Alpha
Sentiment: Positive
HIMS' steep correction is well warranted, given the expensive valuations and the headwinds from the now available FDA-approved GLP-1 therapies. However, we believe that the end of GLP-1 shortage is a tailwind, allowing its core personalized healthcare portfolio to shine, as observed in the double digits non-GLP-1 revenue growth. The same has been observed in the rich FY2024 performance metrics and the management's FY2025 guidance, as they seek to expand their vertically integrated healthcare offerings.
Read More
Why Hims & Hers Health Stock Sank This Week
Published: February 28, 2025 by: The Motley Fool
Sentiment: Negative
Shares of Hims & Hers Health (HIMS 6.76%) sank 10.5% this week, according to data from S&P Global Market Intelligence. The telehealth company that sells dermatology, sexual health, and weight loss drugs directly to consumers posted strong growth for the fourth quarter of 2024 but has investors concerned over the legality of its weight loss drug compounds.
Read More
Wall Street's Most Wanted: 2 Highly Shorted Stocks Right Now
Published: February 26, 2025 by: MarketBeat
Sentiment: Negative
Short-selling is an interesting part of the stock market that can be dangerous and even controversial. Investors selling shares short are hoping that the price of certain stocks falls so that they can make a profit.
Read More
Hims & Hers Health: Focus On The Future, Not GLP-1s
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health, Inc. reported strong growth, with Q4 sales up $80 million sequentially, yet HIMS stock fell due to GLP-1 business confusion. The online health and wellness platform guided to $2.3 billion in 2025 revenues and $300 million in adjusted EBITDA despite the FDA ending GLP-1 shortages. Hims' non-GLP-1 sales grew 43% to $1.2 billion, showing its business isn't reliant on GLP-1 sales.
Read More
HIMS Stock Craters – Is It a Buying Opportunity?
Published: February 25, 2025 by: 24/7 Wall Street
Sentiment: Negative
Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn't guarantee it would be able to continue selling its knockoff versions of weight-loss drugs Ozempic and Wegovy.
Read More
Hims Stock Crashed After Earnings. What Went Wrong?
Published: February 25, 2025 by: The Motley Fool
Sentiment: Negative
In this video, I will go over the fourth-quarter earnings report from Hims & Hers (HIMS -27.60%) and explain why the stock crashed on Tuesday. Watch the short video to learn more, consider subscribing, and click the special offer link below.
Read More
Hims & Hers Stock Crashed 26% Today. Here's What You Need to Know
Published: February 25, 2025 by: The Motley Fool
Sentiment: Negative
Hims & Hers (HIMS -27.66%) continues to grow at an astounding rate as the company grows subscribers and revenue per subscriber. But Hims & Hers stock is falling after earnings because investors are concerned about the future of GLP-1s.
Read More
Hims & Hers shares plunge 28% on concerns over weight loss business, margins
Published: February 25, 2025 by: CNBC
Sentiment: Negative
Hims & Hers shares fell on Tuesday, a day after the company released fourth-quarter results that disappointed on gross margin and outlined changes to its weight loss business. The company reported $481 million in revenue for the quarter, up 95% from $246.6 million during the same period last year.
Read More
Hims & Hers CFO talks Q4 earnings
Published: February 25, 2025 by: Yahoo Finance
Sentiment: Neutral
Hims & Hers Health (HIMS) stock is dropping in extended hours upon the telehealth company's fourth quarter earnings release, topping revenue ($481.14 million vs. forecasts of $470.39 million) and total subscribers estimates (2.23 million vs.
Read More
Bitcoin Concerns, SPX Upside to "$6030" & HIMS Sinks
Published: February 25, 2025 by: Schwab Network
Sentiment: Negative
As Bitcoin (/BTC) falls to 3-month lows, Kevin Green points to fundamental factors that are weighing on its price activity. He says the technical setup indicates possible selling pressure remains for popular crypto asset.
Read More
Hims & Hers Earnings: Very Strong Business, In A Very Crowded Trade
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers experienced a sell-off due to profit-taking and weaker-than-expected EBITDA margins, despite strong revenue growth. The company is projected to generate over $2 billion in revenues and $350 million in free cash flow in 2025, with no debt. While EBITDA margins have fluctuated, free cash flow remains strong, making the stock attractive at 26x forward free cash flow.
Read More
Hims & Hers: Why This Q4 Earnings Dip Is A Buying Opportunity
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers stock fell ~19% post-Q4 earnings despite revenue beating expectations and EPS aligning with estimates, attributed to gross margin concerns and potential dependency on GLP-1 for future growth. The company's growth remains strong, with a 95% YoY revenue increase, an expanding subscriber base, and higher revenue per subscriber, indicating robust market capture and customer loyalty. Future potential is promising with new service additions, a vast addressable market, and strategic diversification, mitigating risks from competition and regulatory changes.
Read More
Hims & Hers: Post Earnings Drop Is Very Welcomed
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers reported a double beat with Q4 revenue at $481M, a 95% YoY improvement, but faced an 18% stock drop after hours. Despite margin contraction due to new weight loss offerings, adjusted EBITDA increased 163% YoY, highlighting long-term growth potential. Management's goal of 10 million subscribers in 5–6 years, with AI integration and Trybe Labs acquisition, presents a bullish opportunity.
Read More
Compared to Estimates, Hims & Hers Health (HIMS) Q4 Earnings: A Look at Key Metrics
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Hims & Hers Health (HIMS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Hims & Hers warns its supply of compounded weight loss drugs could be 'constrained'
Published: February 24, 2025 by: Reuters
Sentiment: Negative
Hims & Hers said the U.S. FDA's decision that the shortage of Novo Nordisk's weight-loss and diabetes drugs had been resolved could constrain the telehealth firm's ability to continue providing access to compounded versions of the drugs on its platform once current inventory has been sold.
Read More
Hims & Hers offers upbeat forecast, but stock slides after hours
Published: February 24, 2025 by: Market Watch
Sentiment: Neutral
Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street's expectations, but shares fell hard in after-hours trading, in an echo of Friday's sell-off amid concerns about the fate of its Ozempic alternatives.
Read More
Hims & Hers shares tumble 18% as margin miss adds to concerns about GLP-1 business
Published: February 24, 2025 by: CNBC
Sentiment: Negative
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended trading. The company's margin of
Read More
Here's Why Hims & Hers Health, Inc. (HIMS) is a Strong Momentum Stock
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Hims & Hers Declines - How The GLP-1 Market Shift Affects Growth
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Negative
Hims & Hers Health stock dropped 25% after the FDA announced the end of the semaglutide shortage, impacting Hims' weight loss services revenue. Hims plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide and tirzepatide. Despite the setback, Hims shows strong financial health with 77% Y/Y revenue growth and no long-term debt, warranting a "hold" recommendation.
Read More
Why Hims & Hers Health Stock Is Plummeting Today
Published: February 21, 2025 by: The Motley Fool
Sentiment: Negative
Shares of Hims & Hers Health (HIMS -24.30%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m.
Read More
Shares of Hims & Hers tumble 23% after FDA says semaglutide is no longer in shortage
Published: February 21, 2025 by: CNBC
Sentiment: Negative
The FDA announced on Friday that the shortage of semaglutide injection products like Novo Nordisk's Ozempic and Wegovy has been resolved. The FDA said Friday that it will start taking action against compounders for violations in the next 60 to 90 days.
Read More
Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?
Published: February 21, 2025 by: 24/7 Wall Street
Sentiment: Positive
“The Next NVIDIA” Could Change Your Life NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
Read More
Hims and Hers Stock Drops Weight as Earnings Loom
Published: February 21, 2025 by: Schaeffers Research
Sentiment: Negative
Hims & Hers Health Inc (NYSE:HIMS) stock has had a roller coaster week.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Household & Personal Products
- CEO Mr. Andrew Dudum
- Employees 1637